Homozygous SCA 2 mutations changes phenotype and hastens progression.
Ragothaman
Mona
M
Muthane
Uday
U
D000978:Antiparkinson Agents / Q000627:therapeutic use; D000067528:Ataxins; D003704:Dementia / Q000175:diagnosis / Q000235:genetics; D018450:Disease Progression; D020820:Dyskinesias / Q000175:diagnosis / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006720:Homozygote; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics*; D015835:Ocular Motility Disorders / Q000175:diagnosis / Q000235:genetics; D020734:Parkinsonian Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D010641:Phenotype; D011618:Psychotic Disorders / Q000175:diagnosis / Q000235:genetics; D013132:Spinocerebellar Degenerations / Q000235:genetics* / Q000503:physiopathology*
D000978:Antiparkinson Agents; D000067528:Ataxins; D009419:Nerve Tissue Proteins; D007980:Levodopa